Regulation of Progranulin Expression in Human Microglia and Proteolysis of Progranulin by Matrix Metalloproteinase-12 (MMP-12) by Suh, Hyeon-Sook et al.
Regulation of Progranulin Expression in Human
Microglia and Proteolysis of Progranulin by Matrix
Metalloproteinase-12 (MMP-12)
Hyeon-Sook Suh*, Namjong Choi, Leonid Tarassishin, Sunhee C. Lee
Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America
Abstract
Background: The essential role of progranulin (PGRN) as a neurotrophic factor has been demonstrated by the discovery that
haploinsufficiency due to GRN gene mutations causes frontotemporal lobar dementia. In addition to neurons, microglia in
vivo express PGRN, but little is known about the regulation of PGRN expression by microglia.
Goal: In the current study, we examined the regulation of expression and function of PGRN, its proteolytic enzyme
macrophage elastase (MMP-12), as well as the inhibitor of PGRN proteolysis, secretory leukocyte protease inhibitor (SLPI), in
human CNS cells.
Methods: Cultures of primary human microglia and astrocytes were stimulated with the TLR ligands (LPS or poly IC), Th1
cytokines (IL-1/IFNc), or Th2 cytokines (IL-4, IL-13). Results were analyzed by Q-PCR, immunoblotting or ELISA. The roles of
MMP-12 and SLPI in PGRN cleavage were also examined.
Results: Unstimulated microglia produced nanogram levels of PGRN, and PGRN release from microglia was suppressed by
the TLR ligands or IL-1/IFNc, but increased by IL-4 or IL-13. Unexpectedly, while astrocytes stimulated with proinflammatory
factors released large amounts of SLPI, none were detected in microglial cultures. We also identified MMP-12 as a PGRN
proteolytic enzyme, and SLPI as an inhibitor of MMP-12-induced PGRN proteolysis. Experiments employing PGRN siRNA
demonstrated that microglial PGRN was involved in the cytokine and chemokine production following TLR3/4 activation,
with its effect on TNFa being the most conspicuous.
Conclusions: Our study is the first detailed examination of PGRN in human microglia. Our results establish microglia as a
significant source of PGRN, and MMP-12 and SLPI as modulators of PGRN proteolysis. Negative and positive regulation of
microglial PGRN release by the proinflammatory/Th1 and the Th2 stimuli, respectively, suggests a fundamentally different
aspect of PGRN regulation compared to other known microglial activation products. Microglial PGRN appears to function as
an endogenous modulator of innate immune responses.
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Introduction
Progranulin (PGRN) is a growth factor widely expressed in
mammalian tissues with highest levels in epithelial and myeloid
cells [1–3], where it is involved in cell proliferation, wound healing
and modulation of inflammation [4,5]. PGRN contains seven and
half granulin domains connected by linker regions. Proteolytic
cleavage of PGRN by neutrophil elastase or proteinase 3 generates
,6 kDa granulins and other molecular weight peptides [1,2,5–8].
This process can be inhibited by secretory leukocyte protease
inhibitor (SLPI) [8]. The full-length PGRN and granulin peptides
have been shown to have opposite roles in inflammation [7,9]. For
example, during wound healing, PGRN inhibits neutrophil
activation by TNFa but granulins promote epithelial production
of neutrophil chemoattractant IL-8 [8].
PGRN has gained much attention with the discovery that
haploinsufficiency resulting from the GRN gene mutations can
cause frontotemporal lobar degeneration (FTLD) [10–12], indi-
cating that adequate expression of PGRN is essential for normal
CNS aging. PGRN is expressed primarily by neurons and
microglia in the CNS [2]. Increased microglial PGRN immuno-
reactivity is reported in several human CNS diseases including
Alzheimer’s disease, multiple sclerosis, FTLD, and HIV enceph-
alitis [10,13,14] (HS and SCL, unpublished). A detailed analysis of
PGRN mRNA in FTLD brains showed an overall increase
indicating that PGRN transcription from the normal allele can be
upregulated and that PGRN might be separately regulated in
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dysregulated in the periphery in patients with CNS diseases. For
example, peripheral blood PGRN mRNA levels are increased in
AD patients [17], whereas plasma PGRN protein levels are
reportedly decreased in children with autism [18]. The cellular
origins and the molecular mechanisms behind PGRN dysregula-
tion in these patient populations are largely unexplored.
To model FTLD caused by genetic PGRN deficiency, gene
knockout (Grn2/2) mice have been generated and characterized.
While these studies support the general idea that PGRN
contributes to normal aging, the CNS abnormalities in these mice
are quite subtle [19–21]. In addition to increased gliosis and
senescence, Grn2/2 mice also show exaggerated inflammation
and impaired host defense. Specifically, LPS-challenged Grn2/2
macrophages reportedly produce higher amounts TNFa and IL-6
but less IL-10 [20]. Grn2/2 mice also show defective bacterial
clearance from the brain [20]. Other somewhat conflicting results
are also reported, including PGRN being a necessary cofactor for
TNFa and IL-6 production in mouse macrophages challenged
with the TLR9 ligand [22]. In human macrophages, Okura et al.,
reported that PGRN augmented TNFa and IL-1b expression [23].
Other aspects of macrophage biology that have been shown to be
affected by PGRN include phagocytosis [2,24], migration [4,25],
and TNFa signaling [26]. PGRN has also been implicated in the
regulation of phagocytosis of apoptotic neurons (programmed cell
death) during C. elegans development [27].
Despite the importance of microglial PGRN in the CNS, little
information is available regarding the regulation of expression and
function of PGRN in microglia. In the current study, we examined
PGRN production and proteolytic cleavage in primary cultures of
human microglia, as well as its role in LPS- and poly IC-induced
cytokine production. The results of this study are consistent with
the idea that microglial PGRN is a necessary factor for the CNS
innate immune responses.
Results
Expression of PGRN by cultures of primary human
microglia (Figure 1)
Microglial cultures were treated with different types of
inflammatory stimuli: Th1 cytokine (IFNc), Th2 cytokines (IL-4
or IL-13), TLR ligands (poly IC or LPS) or pro-inflammatory
cytokine (IL-1b). PGRN expression was examined by ELISA,
western blot and Q-PCR. ELISA data from a representative
microglial case and normalized pooled data from multiple
microglial cases (all 24 h stimulation) are shown in Figure 1A
and B, respectively. Microglia constitutively secreted nanogram
levels of PGRN (also see below), which were suppressed by LPS,
poly IC or IL-1/IFNc or increased by IL-4 or IL-13. The most
consistent change was suppression of PGRN secretion by LPS
(,50% reduction, p,0.001). A representative western blot
(intracellular PGRN) is shown in Figure 1C (24 h post-stimula-
tion). A dominant band corresponding to ,90 kDa, consistent
with reported glycosylated PGRN [1,2] was detected in all
microglial samples. The results show a trend similar to ELISA
data, i.e., suppression by proinflammatory stimuli (IL-1/IFNc,
LPS and poly IC), but preservation by the Th2 cytokines (IL-4 or
IL-13). Figure 1D is a pooled normalized Q-PCR data (6 h
stimulation) showing significant inhibition by LPS and poly IC.
TNFa mRNA was determined as an internal control for cytokine/
TLR ligand activity (Figure 1E). Together, these results in
microglia show that proinflammatory stimuli (particularly the
TLR3/4 ligands) suppress PGRN expression, and that the Th2
cytokines either preserve or even elevate secreted PGRN levels (see
Discussion).
Expression of PGRN by human fetal astrocytes (Figure 2)
Astrocyte cultures were also examined for PGRN expression,
essentially as described for microglia, except LPS was omitted
because human astrocytes are non-responsive to LPS. The
amounts of secreted PGRN in untreated astrocyte cultures were
significantly lower than those in microglial cultures (average 1.98
versus 13.04 ng/ml), with many cases showing pg/ml levels
(Figure 2A). Interestingly, however, astrocyte PGRN showed a
response opposite of microglia, i.e., enhancement by proinflam-
matory stimuli (IL-1/IFNc or poly IC). Results of ELISA assay are
shown in Figure 2B. Pooled Q-PCR data are shown in Figure 2C.
TNFa mRNA expression was shown as a control (Figure 2D). For
astrocyte PGRN production, poly IC appeared to be more potent
stimulus than IL-1/IFNc, whereas for astrocyte TNFa, IL-1/IFNc
was a much stronger stimulus than poly IC.
PGRN is cleaved by macrophage elastase MMP-12 in
human microglia (Figure 3)
In the periphery, PGRN has been shown to be cleaved to
smaller granulin peptides by proteolytic enzymes such as
neutrophil elastase or proteinase-3 [7,8]. PGRN cleavage by
microglial enzymes has not been examined. We therefore tested
whether macrophage elastase MMP-12 could degrade PGRN. We
first examined microglial culture (cell lysates and cell supernatants)
for PGRN degradation products by immunoblotting with an
antibody against C-terminal PGRN (Figure 3A). Culture super-
natants were concentrated using a centrifugal filter device with a
3 kDa molecular weight cutoff. The blots were probed for PGRN,
MMP-12 and b-actin. Figure 3A PGRN blot with short exposure
(top panel) shows results similar to those shown in Figure 1B, with
a predominant band consistent with ,90 kDa [2]. The secreted
PGRN had slightly higher molecular mass, possibly indicating
additional protein modifications prior to secretion. Upon long
exposure (middle panel), multiple PGRN cleavage products were
apparent (,45 kDa, 42 kDa, 35 kDa and 25 kDa) in cell lysates
but not in culture supernatants. Importantly, while LPS reduced
the amount of PGRN in both cell lysates and supernatants (top
panel), it increased the amount of PGRN cleavage products
(middle panel).
The enzyme responsible for PGRN cleavage in microglia or
macrophages is not known. We tested a candidate enzyme MMP-
12 (macrophage elastase) in our culture. Western blot analysis
showed that MMP-12 protein is present in both control and LPS-
treated microglia in intracellular and extracellular compartments
(Figure 3A, bottom panel). The proenzyme for MMP-12 is
,54 kDa, and is rapidly activated to a 45 kDa form, and later to a
22 kDa form, and microglial cell lysates show all three bands, as
well as an additional ,35 kDa band [28–30], while the secreted
MMP-12 was consistent with the MMP-12 proenzyme (54 kDa).
Figure 3B shows Q-PCR analysis of microglial MMP-12, which
showed that both LPS and poly IC significantly increased the
amount of MMP-12 mRNA. Together, these results show that in
microglia MMP-12 and PGRN cleavage (activation) occurs mostly
intracellularly (see Discussion), consistent with the idea that
microglial PGRN is cleaved by MMP-12. LPS increases PGRN
cleavage, while reduces the amount of total PGRN.
PGRN interacts with MMP-12 in microglia (Figure 4)
To determine the possible molecular interaction between
PGRN with MMP-12 directly, we performed immunoprecipita-
Proinflammatory Factors Suppress Progranulin
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lysates were immunoprecipitated with a rabbit C-terminal PGRN
antibody, then immunoblotted for PGRN and MMP-12. To avoid
the interference from denatured IgG, clean-blot IP detection
reagent was used for detection of the target antigens. Microglial
cell lysates showed ,90 kDa PGRN and ,54, 45 and 22 kDa
MMP-12 bands consistent with the data in Figure 3A (lane 1).
Following IP with anti-PGRN, all three MMP-12 bands were
detected, with the ,45 kDa band being the most prominent.
These results show that PGRN and (active) MMP-12 physically
interact in microglia and further strengthen the idea that MMP-12
cleaves PGRN.
Figure 1. Proinflammatory stimuli suppress microglial PGRN expression. Microglial cultures were treated with IFNc 6 IL-1 (10 ng/ml each),
LPS (100 ng/ml), poly IC (10 mg/ml), IL-4 (10 ng/ml), IL-13 (10 ng/ml) or medium alone (control). PGRN expression was examined by ELISA (A & B),
western blot (C) or Q-PCR (D &E). Representative ELISA data from a single microglial case are shown in (A), and pooled data from 3–8 different cases
are shown in (B) (all 24 h stimulation). All samples were tested in triplicates. (C) Representative western blot (24 h stimulation). Densitometric ratios to
b-actin are shown below the blot. (D) Pooled normalized Q-PCR data (6 h stimulation) for PGRN from 3 different cases are shown. (E) TNFa mRNA data
are shown as a control. Data are mean 6 SD. One-way ANOVA with Dunnett’s multiple comparison tests was performed for (A). For all others
(normalized data), one sample t-test was performed. * p,0.05, ** p,0.01, ***p,0.001. The results show that microglial PGRN is suppressed by
proinflammatory stimuli.
doi:10.1371/journal.pone.0035115.g001
Proinflammatory Factors Suppress Progranulin
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35115MMP-12 cleaves recombinant PGRN (Figure 5)
We next examined whether MMP-12 can cleave PGRN in a
cell-free system. Recombinant human (rh) PGRN was incubated
with activated rhMMP-12 in a specified assay buffer for 40 min or
18 h at 37uC. The samples were fractionated in a 4–15% gradient
gel. Figure 5A shows that only in the presence of MMP-12, PGRN
cleavage occurred. Five major molecular species (,45 kDa,
35 kDa, 25 kDa, 19 kDa and 12 kDa) of PGRN degradation
products were detected at 40 min, with the ,19 kDa band
becoming intense at 18 h. Figure 5B shows MMP-12 dose-
dependent (0.01–0.3 mM, 2 h post incubation) degradation of
PGRN.
The effect of SLPI on MMP-12-induced PGRN cleavage
(Figure 6)
We next examined whether SLPI inhibits MMP-12-induced
PGRN cleavage. PGRN was incubated with activated MMP-12
with and without SLPI in a specified assay buffer for 40 min at
37uC, as described in the Methods section. Western blot was
performed for PGRN and SLPI. Figure 6 shows that PGRN
(0.1 mM) was cleaved only in the presence of MMP-12 (0.1 mM)
and this was inhibited by SLPI in a dose-dependent manner
(0.5 mM–2.5 mM). At 2.5 mM, SLPI appeared to have induced
polymerization of PGRN (,240 kDa) to prevent degradation.
Furthermore, we find that SLPI was cleaved by MMP-12, both in
the presence and absence of PGRN.
SLPI expression by human astrocytes and microglia
(Figure 7)
SLPI is a multifunctional protein with many important
biological activities but whether SLPI is produced by the cells in
the CNS is unknown. Therefore, SLPI expression was determined
in astrocyte and microglial cultures. A representative ELISA data
(24 h) is shown in Figure 7A. Surprisingly, while astrocytes
produced ng/ml levels of SLPI following proinflammatory
Figure 2. Proinflammatory stimuli enhance astrocyte PGRN Expression. Astrocyte cultures were treated with IFNc 6 IL-1, poly IC, IL-4, IL-13
or medium alone (control) and PGRN expression was examined by ELISA and Q-PCR. (A) Secreted PGRN levels in control microglia and astrocyte
cultures determined by ELISA (24 h) show that microglia produce larger amounts of PGRN than astrocytes. Each symbol represents a different case.
(B) Representative ELISA data from cytokine-stimulated astrocyte cultures (24 h stimulation). (C, D) Pooled normalized Q-PCR data for PGRN and TNFa
from astrocyte cultures (6 h stimulation, n=5) are shown. Data are mean 6 SD. * p,0.05, ** p,0.01, *** p,0.001. The results show that
proinflammatory stimuli induce astrocyte PGRN production.
doi:10.1371/journal.pone.0035115.g002
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ml). By Q-PCR (6 h), astrocytes expressed high levels of SLPI
mRNA following stimulation with IL-16IFNc or poly IC (pooled
normalized data) consistent with the ELISA data (Figure 7B).
Although SLPI mRNA induction was detectable in microglia
following LPS or poly IC stimulation, the levels were ,100-fold
lower than those detected in astrocytes (Figure 7B). These results
show that although in rodents, macrophages are the major source
of SLPI [31], human microglia (and monocyte-derived macro-
phages, n=3, not shown) do not make significant amounts of
SLPI. Rather, astrocytes appear to be the main producer of SLPI
in human CNS cell cultures.
Microglial PGRN is an endogenous cofactor for cytokine
and chemokine production following TLR3/4 stimulation
(Figures 8 and 9)
Given the recent evidence that PGRN modulates cytokine
production in rodent macrophages [20,22], we asked whether
PGRN modulates microglial cytokine and chemokine production
by employing small-interfering RNA (siRNA). Microglial cultures
treated with PGRN siRNA (72 h) resulted in an average of ,80%
reduction of PGRN production (Figure 8A). Following treatment
with PGRN siRNA (or control non-targeting siRNA), cultures
were further exposed to LPS or poly IC for an additional 24 h.
ELISA was performed for TNFa, IL-6, IL-1b, IL-1 receptor
antagonist (IL-1ra), IP-10, IL-8 and IL-10. Results from a
representative microglial case are shown in Figure 8, and pooled
Figure 3. PGRN is cleaved by macrophage elastase MMP-12 in
human microglia. (A) Microglia were incubated with medium alone
(control) or LPS for 24 h. Culture supernatants were concentrated ,25
fold using a 3 kDa cutoff filter. Equal amounts (30 mg) of protein from
cell lysates and culture supernatants were loaded in each lane. Blots
were probed for PGRN using a C-terminal specific antibody, and for
MMP-12 and b-actin. Data are representative of three independent
experiments with similar results. (B) Microglia cultures were examined
for MMP-12 mRNA expression by Q-PCR (6 h stimulation). Pooled
normalized data from 3 different cases are shown. ** p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0035115.g003
Figure 4. PGRN interacts with MMP-12 in microglia. Microglial
cell lysates (untreated, control culture) were immunoprecipitated (IP)
with anti-PGRN antibody and immunoblotted with anti-PGRN or anti-
MMP-12 antibody. Recombinant MMP-12, PGRN, and non-IP microglial
cell lysates were also analyzed in parallel. Microglial cell lysates show
,90 kDa PGRN and ,54, 45 and 22 kDa MMP-12 bands (arrowheads).
Following IP with anti-PGRN, the ,45 kDa MMP-12 band is prominent,
indicating that PGRN and active MMP-12 interact with each other in
microglia.
doi:10.1371/journal.pone.0035115.g004
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PGRN siRNA are shown in Figure 9. These results together show
that PGRN siRNA reduces the amount of cytokines including
TNFa, IP-10, IL-6, IL-1ra, and possibly IL-1b. The degree of
inhibition varied depending on the cytokine and the stimulus. The
strongest (,50%) and most significant inhibition was found for
TNFa and IP-10. Interestingly, LPS-induced IP-10 but not poly
IC-induced IP-10 was inhibited by PGRN siRNA. IL-1ra was also
inhibited by ,25%, and IL-6 was inhibited by ,10%. PGRN
siRNA had no significant effect on IL-1b, IL-8, or IL-10
production (Figure 9). None of the cytokines were significantly
increased by PGRN siRNA, indicating that endogenous PGRN
had a stimulatory role in microglial cytokine production.
Discussion
To our knowledge, this is the first detailed study of PGRN
production in primary CNS cells. Aside from a study of myeloid
cell lines reporting increase of PGRN mRNA by cell differenti-
ating agents such as retinoic acid and phorbol ester (PMA) [32], no
information is available on the mechanisms that regulate PGRN
production from macrophages or CNS cells. Our in vitro studies of
human fetal microglia and astrocytes show that microglia are the
major source of PGRN but that inflammatory stimuli differentially
regulate PGRN in the two cell types. Thus, our data supports that
microglial PGRN is a constitutively produced neuronal growth
factor. Interestingly, the TLR ligands (LPS and poly IC were
examined) and the proinflammatory/Th1 cytokines (IL-1/IFNc)
suppressed microglial PGRN, while they increased PGRN
production from astrocytes. Human GRN promoter contains
several consensus sequences involved in cytokine and growth-
factor-regulated gene expression, including IL-6 response element,
NFL-IL-6 binding sites, and TGFb-1 inhibitory element [33,34].
The large number and variety of putative regulatory elements
implies considerable complexity and versatility in the regulation of
expression of the gene GRN [33]. The astrocyte response to IL-1/
IFNc is similar to that of mouse embryonic fibroblasts which
showed PGRN induction by TNFa or IL-1b [35], but there is no
precedent for the observed suppression of PGRN by inflammatory
mediators. While proinflammatory mediators suppressed PGRN,
the Th2 cytokines (IL-4 and IL-13) increased PGRN production in
microglia, as determined by ELISA. The differential regulation by
Th1 vs. Th2 cytokines is in keeping with the reported differential
effects of IFNc (decrease) and IL-4 (increase) in murine microglial
IGF-1 [36]. These results suggest the presence of common
regulatory elements that control the expression of neuronal growth
factors in microglia. The contrasting responses of astrocytes and
microglia also indicate that PGRN regulation in monocyte-lineage
cells is different from that in epithelial cells and fibroblasts.
Unlike PGRN, its proteolytic products granulins are reported to
have proinflammatory activities. The details of granulin produc-
tion and biological consequences have been studied in neutrophils
and epithelial cells [1,4,8]. In microglia, we show that PGRN
cleavage occurs intracellularly and this is increased by LPS,
although LPS suppressed the total amount of PGRN. These results
support the scenario that under inflammatory CNS conditions,
PGRN production is suppressed while granulin production is
increased, switching the role of microglia from a neurotrophic one
to an inflammatory one. In order to understand the role of PGRN,
we employed PGRN siRNA to silence its expression and this
Figure 5. MMP-12 cleaves recombinant PGRN. (A) Varying
concentrations of recombinant PGRN (0.05 or 0.1 mM) were incubated
with or without activated recombinant MMP-12 (0.1 mM) in a specified
assay buffer at 37uC for 40 min or 18 h. Samples were fractionated
using a 4–15% gradient gel. (B) MMP-12 dose response: PGRN was
incubated with increasing concentrations (0.01–0.3 mM) of MMP-12 for
2 h, then separated using a 4–15% gradient gel. In both samples, five
different PGRN cleavage products were noted corresponding to
,45 kDa, 35 kDa, 25 kDa, 19 kDa and 12 kDa (arrowheads).
doi:10.1371/journal.pone.0035115.g005
Figure 6. Inhibition of MMP-12-mediated PGRN cleavage by
SLPI. Recombinant PGRN (0.1 mM) was incubated with activated MMP-
12 (0.1 mM) with or without SLPI at indicated doses (0.5–2.5 mM) for
40 min at 37uC. Western blot was performed for PGRN and SLPI. Results
show that MMP-12 mediated PGRN cleavage was dose-dependently
inhibited by SLPI. Data are representative of three separate experiments
with similar results.
doi:10.1371/journal.pone.0035115.g006
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these experiments showed that PGRN positively regulated TLR3/
4-induced cytokine and chemokine production. Its effect on TNFa
production was most notable. In addition, IP-10, IL-6 and IL-1ra
were affected, while IL-1, IL-8 and IL-10 were not affected. This is
fitting with the notion that PGRN/granulin contributes to the
CNS innate immune responses, rather than inhibiting cytokine
production, as has been maintained previously [20].
The profound effect of microglial PGRN in the induction of
TNFa shown here probably reflects the complex role of TNFa in
the TLR signaling. Following LPS stimulation, initial TNFa
production has an important role in early autocrine activation of
macrophages [37]. PGRN has recently been found to directly bind
to TNFa receptors thereby suppressing TNFa receptor signaling
[26]. The role of TNFa in immunity and inflammation is also
highly complex. While proven to be harmful in rheumatoid
arthritis, it was found to be beneficial in multiple sclerosis patients
[38–41]. IL-6 also has a complex biological activity. For example,
IL-6 induces Th17 differentiation of T cells thereby contributing
to autoimmunity, but it also has a neurotrophic activity shared by
other gp130 cytokines [42]. IP-10 is a principal chemoattractant
for T cells thus is crucial in inflammatory responses, but it has
demonstrated detrimental effects on neurons [43]. Our data also
suggests that PGRN might contribute to IL-1 antagonism.
Therefore, PGRN may help maintain the differential cytokine
balance (TNFa, IP-10, IL-6.IL-1) and fine tune the CNS
inflammatory response, without compromising the integrity of
neural elements.
Our study also establishes PGRN as a MMP-12 substrate.
Previously, PGRN has been shown to be cleaved by MMP-14
[44], MMP-9 [45], and ADAMTS7 [46], in addition to neutrophil
elastase [8], thus it is likely that multiple enzymes (in addition to
MMP-12) can generate granulins in the CNS. Curiously,
microglial MMP-12 activation and PGRN cleavage occurred
intracellularly but not extracellularly. MMP-12 activity is regulat-
ed by several factors including Ca
2+ concentration and pH [47],
thus it is most likely that extracellular PGRN proteolysis will occur
under the conditions that sharply increase the Ca
2+ levels such as
during inflammation and cell death [48].
In our study, astrocyte PGRN was increased by IL-1/IFNc or
poly IC, contrary to microglia. Astrocytes contribute considerably
less to the overall PGRN pool in the CNS on a per cell basis.
Despite our observations, astrocyte contribution to PGRN
production in vivo might be even smaller, since astrocytes are
infrequently observed to be immunoreactive for PGRN in the
CNS. The role of astrocytes may be more important as a source of
SLPI, an inhibitor of PGRN proteolysis. We show that
recombinant SLPI is effective in inhibiting MMP-12-induced
PGRN cleavage, though high molar excess (to MMP-12) was
required. SLPI at high concentrations caused a shift in PGRN
molecular mass, probably reflecting polymerization. In addition,
MMP-12 also caused a partial cleavage of SLPI [49], establishing
SLPI as another MMP-12 substrate. Therefore, complex interac-
tions involving PGRN, MMP-12 and SLPI are likely to occur in
vivo.
Another surprising finding of our study is that human microglia
produced little or no SLPI. In rodents, macrophages have been
shown to be a significant source of SLPI [31,50,51]. Few reports
exist that demonstrate SLPI production by human macrophages
[52]. It is possible that in human microglia (and likely
macrophages), SLPI expression is silenced, akin to iNOS
expression in human macrophages [53]. In addition to its anti-
proteolytic activities, SLPI has other known functions, such as
inhibition of HIV [54] and suppression of macrophage activation
[31]. For example, extracellular SLPI has been shown to be taken
up by macrophages, translocate to the nucleus, and inhibit NF-kB
activation and cytokine production [31]. Therefore, astrocyte
SLPI might counteract various aspects of microglial activation in
Figure 7. SLPI expression by human astrocytes and microglia.
Astrocyte or microglial cultures were treated with IFNc 6 IL-1, LPS, poly
IC, IL-4 or IL-13 and SLPI expression was examined by ELISA (24 h) or Q-
PCR (6 h stimulation). (A) Representative ELISA data from astrocytes and
microglia are shown. Results show that SLPI is produced by activated
astrocytes. Results are mean 6 SD and are representative of 3–5
separate cases. (B) Pooled normalized Q-PCR data (n=3) show that SLPI
mRNA was induced by proinflammatory stimuli (astrocytes..micro-
glia). * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0035115.g007
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microglia (and macrophages) might render these cells more prone
to proinflammatory activation.
Our study sheds light into the PGRN biology in human CNS
cells, but also opens up several important questions, such as the
molecular mechanisms underlying microglial PGRN gene repres-
sion, and the signals that upregulate microglial PGRN expression
in vivo. It is also unclear whether neuronal PGRN is under similar
regulation. The fundamentally different role of microglial
(macrophage) PGRN in inflammation (as opposed to PGRN’s
generally implicated neurotrophic role) might suggest that neuron-
autonomous PGRN is important in the maintenance of normal
neuronal physiology. The results also suggest that complete
absence of PGRN in Grn2/2 mice may not accurately reflect
the relationship between neuronal and microglial PGRN (such as
that occurs in FTLD), due to abolition of the reactive PGRN arm.
Future studies addressing these issues could aid the understanding
of the mechanism by which PGRN deficiency leads to neurode-
generation in FTLD.
Materials and Methods
Ethics Statement
Human tissue collection was approved by the Albert Einstein
College of Medicine Institutional Review Board (IRB#: 1994-
019). Informed written consent was obtained from all participants
involved in the study.
Primary human microglial and astrocyte culture
Human cell cultures were prepared from human fetal abortuses
as described with minor modifications [55]. All tissue collection
was approved by the Albert Einstein College of Medicine
Institutional Review Board. Primary mixed CNS cultures were
prepared by enzymatic and mechanical dissociation of the cerebral
tissue followed by filtration through nylon meshes of 230- and 130-
m pore sizes. Single cell suspension was plated at 1–10610
6 cells
per ml in DMEM (Cellgro, Mediatech) supplemented with 10%
FBS (Gemini Bio-products, Woodland, CA), penicillin (100 U/
ml), streptomycin (100 mg/ml) and fungizone (0.25 mg/ml)
(complete medium) for 2–3 weeks, and then microglial cells were
collected by aspiration of the culture medium. Monolayers of
microglia were prepared in 60-mm tissue culture dishes at 1610
6
cells per 5 ml medium or in 96-well tissue culture plates at 3–
4610
4 per 0.1 ml medium. Four to sixteen hours later, cultures
were washed to remove non-adherent cells (neurons and
astrocytes). Microglial cultures were highly pure consisting of
.98% CD68
+ cells. Highly enriched human astrocyte cultures
were generated by repeated passage of the mixed CNS cultures, as
described previously [56]. All cultures were kept as monolayers in
DMEM with 5% FCS and antibiotics.
Cell stimulants and culture treatment
LPS and poly IC were from Sigma-Aldrich (St. Louis, MO),
recombinant human (rh) IL-1b, IL-4, IL-13 and IFNc were from
Peprotech (Rocky Hill, NJ). PGRN, MMP-12, and SLPI were
from R&D systems (Minneapolis, MN). Culture media were
changed to low serum media (DMEM+0.2% FBS) 24 h prior to
cell stimulation. All cytokines were used at 10 ng/ml, poly IC at
10 mg/ml, and LPS at 100 ng/ml. MMP-12 was incubated with
assay buffer (50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05%
Brij-35, pH 7.5) at 37uC for 30 h to activate enzyme, following the
manufacturer’s protocol (R&D Systems).
Concentration of culture supernatants
Culture supernatants were concentrated ,25 fold using a
centrifugal filter device (Amicon Ultra 3K) from Millipore
(Billerica, MA), according to the manufacturer’s protocol. Protein
concentration was quantified using the Bradford (Bio-Rad) assay.
Figure 8. Role of microglial PGRN in TLR3/4-mediated cytokine production. Microglial cultures were treated with siRNA specific for human
PGRN (PGRN-si: white symbol) or a control non-targeting siRNA (cont-si: black symbol) for 3 days. Cultures were then stimulated with LPS or poly IC
for additional 24 h. (A) PGRN ELISA was performed to determine the effect of PGRN-si in microglia. (B to H) TNFa, IL-6, IL-1b, IL-1ra, IL-10, IP-10 and IL-
8 were measured by ELISA in the same culture. Results from a representative experiment are shown. Data are mean 6 SD from triplicate samples
(* p,0.05, ** p,0.01, ***p,0.001). The results show that PGRN-si reduces the production of multiple cytokines and chemokines induced by LPS or
poly IC.
doi:10.1371/journal.pone.0035115.g008
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Western blot analysis was performed as previously described
[57] with minor modifications. Briefly, cell cultures in 60 mm
dishes were scraped into lysis buffer (Tris-sucrose buffer, pH 7.4)
Thirty to fifty micrograms of protein was separated by 12%
sodium dodecyl sulfate-polyacrylamide gel. For immunoblotting of
recombinant proteins, 4–15% gradient gels (Bio-Rad: Hercules,
CA) were used. Proteins were transferred to polyvinylidene
difluoride membranes (Millipore Inc.). The membranes were
blocked in PBS-0.1% Tween-20 containing 5% nonfat milk and
then incubated with antibodies at 4uC for 16 h. Following primary
antibodies were used: rabbit polyclonal IgG against C-terminal
PGRN (Invitrogen: Camarillo, CA) 1:100; goat anti-human (full
length) PGRN IgG (R&D systems) 1:1,000; rabbit anti-human
MMP-12 (Millipore) 1:1,000; and goat anti-human SLPI (Life
science) 1: 250. Secondary antibodies were horseradish peroxi-
dase-conjugated anti-rabbit (Pierce Biotechnology: Rockford, IL)
or anti-goat IgG (Southern Biotechnology Associates: Birming-
ham, AL) at 1:1,000. Signals were developed using enhanced
chemiluminescence (Pierce Biotechnology). All blots were re-
probed for b-actin (Sigma) as a protein loading control.
Densitometric analysis was performed using the ImageJ software
(NIH).
Enzyme-linked immunosorbent assay (ELISA)
IL-1b, TNFa, IL-6, IL-8, IL-10, IL-1ra and IP-10 were
detected using the DuoSets from R&D Systems, as previously
described [58]. PGRN levels were determined using either the
Human PGRN Quantikine ELISA kit (R&D Systems) or the
DuoSet, with similar results. SLPI levels were determined using
Human SLPI Quantikine ELISA kit from R&D Systems
(sensitivity ,25 pg/ml). All samples were diluted until the values
fell within the linear range of the standard.
Real-time PCR
Quantitative real-time reverse transcription-PCR (Q-PCR) was
performed as described previously [57,59], using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and porphobilinogen deam-
inase (PBDA) as internal control. Following primers were used:
PGRN Forward- GAGGACTAACAGGGCAGTGG, Backward-
GCCTCTGGGATTGGACAG; SLPI Forward- CCAGTCA-
CTCTGGCACTCAG, Backward- CTGTGGAAGGCTCTG-
GAAAG; MMP-12 Forward-TGGCCAAGACCTAAGGAATG,
Backward- GATGCACATTTCGATGAGGA. Briefly, total RNA
was extracted with TRIzol (Invitrogen Life Technologies), and
PCR was performed using a SYBR green PCR mix and conducted
with ABI Prism 7900HT (Applied Biosystems). The median value
of the replicates for each sample was calculated and expressed as
the cycle threshold (CT; cycle number at which each PCR reaches
a predetermined fluorescence threshold, set within the linear range
of all reactions). DCT was calculated as CT of endogenous control
gene minus CT of target gene in each sample. The relative amount
of target gene expression in each sample was then calculated as
2
DCT. Fold change was calculated by dividing the value (2
DCT)o f
test sample by the value (2
DCT) of control sample (control=1).
Immunoprecipitation
Microglial cell lysates were pre-incubated with protein A
agarose beads (Thermo Scientific) for 3 h to reduce non-specific
reaction. The supernatants were then mixed with anti-PGRN (C-
terminal) for 1 h. The mixtures were then incubated with protein
A agarose beads (Thermo Scientific) overnight at 4uC. The beads
were boiled in SDS-sample buffer and centrifugated to release the
immune complex. The immunoprecipitates were separated in a
12% SDS polyacrylamide gel. The membranes were immuno-
blotted with anti-rabbit MMP-12 or anti-goat PGRN antibody.
For the immunoprecipitated samples, clean-blot IP detection
reagent (Thermo Scientific Cat#21230), which detects only
specific target antigen without interference from heavy and light
chain (denatured IgG), was used instead of secondary antibodies.
PGRN knockdown by siRNA
Microglia were transfected with 20 nM control non-targeting
small-interfering RNA (siRNA) or human PGRN-specific siRNA
(Dharmacon, Chicago, IL) with transit-TKO transfection reagents
from Mirus (Madison, WI) following the manufacturer’s instruc-
tions. After incubation with siRNA for 3 to 4 days, cells were
washed with fresh medium and then treated with cytokines for an
additional 24 h. ELISA was performed to determine the efficiency
of PGRN knockdown by siRNA.
Figure 9. PGRN modulates TLR3/4-mediated cytokine produc-
tion (pooled data from multiple cases). Microglia were transfected
with control or PGRN siRNA for 3 days, then further treated with LPS (A)
or poly IC (B) for additional 24 h, then cytokines were measured ELISA
as shown in Figure 8. Data are then expressed as % change by PGRN
siRNA as calculated by 1006(PGRN siRNA/control siRNA - 1). Zero
(dotted line) marks no change. Results shown are from multiple
microglial cases with each symbol representing a different case. The
data show that PGRN siRNA reduced the amount of microglial TNFa, IL-
6, IL-1ra and IP-10 induced by LPS, and TNFa and IL-1ra induced by poly
IC. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0035115.g009
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For multiple comparisons, one-way ANOVA with Dunnett’s
multiple comparison tests was performed. For comparison of two
groups, Student’s t-test was performed. For comparing normalized
data, one sample t-test was used to determine whether the changes
were significantly different from control. All data were expressed
as mean (6 SD). P values,0.05 were considered significant:
* denotes p,0.05, ** p,0.01, and *** p,0.001. All statistics were
performed using the GraphPad Prism 5.0 software.
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